Last reviewed · How we verify
INTANZA® 15
At a glance
| Generic name | INTANZA® 15 |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Imiquimod and Influenza Vaccine for Immunocompromised Patients (PHASE2)
- Routes of Immunization and Flu Immune Responses (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |